TNFSF11 and neoplasm: Interestingly, despite differing baseline SRE rates potentially reflecting distinct tumor biology [13,14,21], the on-treatment SRE rates were numerically similar across the groups (8.8–16.0%, p = 0.668), suggesting a consistent effect of RANKL inhibition on suppressing osteoclast activity regardless of the primary tumor, although the underlying bone microenvironment interactions may differ [14].